HLA-DR Antibody (L243): sc-18875

HLA-DR Antibody (L243) is a mouse monoclonal IgG2a kappa light chain antibody engineered to recognize the nonpolymorphic HLA-DR epitope 1-3 on human B lymphocytes. Known also as human leukocyte antigen DR or MHC class II DR, HLA-DR plays a pivotal role in the immune system by presenting antigenic peptides to CD4+ T helper cells, thereby initiating and regulating immune responses essential for pathogen defense and immune surveillance. HLA-DR monoclonal antibody (L243) exhibits exclusive reactivity with HLA-DR molecules, ensuring no cross-reactivity with HLA-DQ or HLA-DP, which enhances precision in various immunological assays. Available in both conjugated and unconjugated forms, anti-HLA-DR antibody (L243) is versatile for applications including immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM), making this tool indispensable for researchers studying immune cell function and antigen presentation. The nonpolymorphic nature of the targeted epitope allows for consistent and reliable detection of HLA-DR across different human samples, facilitating comparative studies and clinical diagnostics. Understanding HLA-DR expression is crucial in fields such as autoimmune disease research, transplantation immunology, and cancer immunotherapy, where antigen presentation and T cell activation are fundamental processes. By utilizing anti-HLA-DR antibody (L243), scientists can gain deeper insights into the mechanisms of immune activation and regulation, ultimately contributing to the development of targeted therapies and diagnostic strategies that enhance patient outcomes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HLA-DR Antibody (L243) References:

1. HLA-DMA and HLA-DMB alleles in German patients with type 1 diabetes mellitus.  |  Siegmund, T., et al. 1999. Tissue Antigens. 54: 291-4. PMID: 10519369
2. The association of HLA-DM genes with rheumatoid arthritis in Eastern France.  |  Toussirot, E., et al. 2000. Hum Immunol. 61: 303-8. PMID: 10689120
3. Functional HLA-DM on the surface of B cells and immature dendritic cells.  |  Arndt, SO., et al. 2000. EMBO J. 19: 1241-51. PMID: 10716924
4. Functional characterization of a lysosomal sorting motif in the cytoplasmic tail of HLA-DObeta.  |  Brunet, A., et al. 2000. J Biol Chem. 275: 37062-71. PMID: 10964920
5. The down-regulation of HLA-DM gene expression in rheumatoid arthritis is not related to their promoter polymorphism.  |  Louis-Plence, P., et al. 2000. J Immunol. 165: 4861-9. PMID: 11046010
6. Determination of the HLA-DM interaction site on HLA-DR molecules.  |  Doebele, RC., et al. 2000. Immunity. 13: 517-27. PMID: 11070170
7. Monoclonal antibodies against human leucocyte antigens. I. Antibodies against beta-2-microglobulin, immunoglobulin kappa light chains, HLA-DR-like antigens, T8 antigen, T1 antigen, a monocyte antigen, and a pan-leucocyte antigen.  |  Horejsí, V., et al. 1986. Folia Biol (Praha). 32: 12-25. PMID: 2422063
8. Characterization of seven new monoclonal antibodies against human DR, DR + DP and DQ1 + DQ3 antigens.  |  Horejsí, V., et al. 1986. Tissue Antigens. 28: 288-97. PMID: 2435017
9. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules.  |  Kropshofer, H., et al. 1998. EMBO J. 17: 2971-81. PMID: 9606180

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-HLA-DR Antibody (L243) has 17 citations in a variety of scientific publications.

Primary antibodies like Anti-HLA-DR Antibody (L243) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

HLA-DR Antibody (L243) Specifications

Alternate Product Name: human leukocyte antigen (HLA) HLA-DR

Product Clone Name: L243

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids:

Epitope Target: HLA-DR

Epitope Species: human

Product Reactivity/Detection: a nonpolymorphic HLA-DR epitope 1-3

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: IF, IHC(P), FCM

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 17 citations in various scientific publications

Available Conjugates/Forms for HLA-DR Antibody (L243): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, APC: Allophycocyanin, FITC: Fluoroscein, PE: Phycoerythrin